A silent hormone disorder may be driving cardiovascular and kidney damage in millions of hypertensive adults who are never tested for it. Primary aldosteronism — where adrenal glands overproduce aldosterone independent of the renin system — is now recognized as far more common than textbooks once suggested, yet detection rates remain strikingly low. Closing this gap could fundamentally change how hypertension is managed at the population level.
A review in Hypertension synthesizes convergent signals across major updated hypertension and endocrine guidelines, which now recommend extending primary aldosteronism screening well beyond the historically narrow criterion of resistant hypertension. The updated threshold encompasses adults with stage 2 hypertension and, in some frameworks, all hypertensive individuals. The aldosterone-to-renin ratio remains the recommended first-line diagnostic test, but guidelines have moved toward more flexible protocols for managing antihypertensive medications prior to testing — a significant practical shift that removes a longstanding clinical barrier. Epidemiological evidence cited in the review demonstrates a continuum of renin-independent aldosterone excess across blood pressure categories, with cardiovascular and renal harms occurring independently of blood pressure elevation itself. Cost-effectiveness modeling reportedly supports screening even in lower-risk populations.
This convergence of guidelines marks a meaningful inflection point, not merely an incremental update. The prior paradigm treated primary aldosteronism as a rare zebra diagnosis; mounting prevalence data repositions it as a common, underdiagnosed endocrine contributor to what is currently labeled essential hypertension. The cardiovascular risk excess — including elevated rates of atrial fibrillation, stroke, and kidney disease — appears to be mechanistically aldosterone-driven rather than pressure-mediated, which means standard antihypertensive therapy without targeted treatment may leave substantial residual risk on the table. Key limitations of this work are its guideline-synthesis nature rather than new trial data, and real-world implementation remains the principal bottleneck, with early electronic health record decision-support tools showing only preliminary promise. Whether broader screening translates to measurable outcomes improvement awaits prospective validation.